Clinical Trial Update: Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of SD-101 with low-dose radiation in untreated low-grade B-cell lymphoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• SD-101

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: B-cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-09-04